JACOBIO-B(01167.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 600.62 million, turned profitable from a loss YoY

August 24, 2026, JACOBIO-B(01167.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 730.87 million, increased by 1500.55% YoY; Net Profit stood at CNY 600.62 million, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 600.62 million, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY 0.78.
In terms of profitability, JACOBIO-B Gross Profit changed from CNY 45.66 million in the same period last year to CNY 712.71 million in the current period, increased by CNY 667.05 million; gross profit margin changed from 100% in the same period last year to 97.51% in the current period, decreased by 2.49 percentage points; net profit changed from loss of CNY 58.99 million in the same period last year to CNY 600.62 million in the current period, increased by CNY 659.62 million; net profit margin changed from -129.19% in the same period last year to 82.18% in the current period, increased by 211.37 percentage points.
In terms of earnings quality, JACOBIO-B Operating Profit changed from loss of CNY 67.02 million in the same period last year to CNY 588.68 million in the current period, increased by CNY 655.7 million; Operating Profit Margin changed from -146.77% in the same period last year to 80.55% in the current period, increased by 227.31 percentage points.
In terms of financial soundness, JACOBIO-B Debt-to-Asset Ratio changed from 32.83% in the same period last year to 27.47% in the current period, decreased by 5.36 percentage points; Total Equity changed from CNY 867.376 million in the same period last year to CNY 1.352 billion in the current period, increased by CNY 484.16 million; Current Liabilities changed from CNY 150.28 million in the same period last year to CNY 208.21 million in the current period, increased by CNY 57.93 million.
In terms of R&D investment focus, JACOBIO-B R&D Expenses changed from CNY 93.22 million in the same period last year to CNY 92.17 million in the current period, decreased by CNY 1.04 million; R&D to Total Revenue Ratio changed from 204.13% in the same period last year to 12.61% in the current period, decreased by 191.52 percentage points.
By the close of trading on August 24, 2026, JACOBIO-B(01167) saw a loss of 1.99% in its share price, closing at HKD 5.16. The full-day turnover stood at HKD 7.99 million, with the latest market capitalization at HKD 4.04 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.